<DOC>
	<DOCNO>NCT00668759</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority vernakalant injection amiodarone injection conversion atrial fibrillation ( AF ) sinus rhythm ( SR ) within 90 minute start drug administration . The secondary objective compare safety vernakalant amiodarone .</brief_summary>
	<brief_title>A Phase III Superiority Study Vernakalant v Amiodarone Subjects With Recent Onset Atrial Fibrillation</brief_title>
	<detailed_description>This double-blind , active-controlled , double-dummy , multi-center , randomized trial subject symptomatic AF 3 48 hour duration . Subjects randomize receive vernakalant injection amiodarone injection 1:1 ratio . Safety assess monitor adverse event , vital sign , continuous telemetry monitoring , 12-lead Holter monitoring , 12-lead ECGs , laboratory test . At 2 hour start infusion , electrical cardioversion may perform rate control medication may administer . Class I Class III antiarrhythmic administer 24 hour start infusion . Subjects remain clinic least 6 hour start infusion . Subjects attend follow-up visit 7 ( ±2 ) day treatment receive follow-up telephone call 30 ( ±3 ) day assessment serious adverse event , concomitant medication relate serious adverse event , recurrence AF . All role blind exception site 's designate unblinded personnel responsible randomization preparation , dispensation accountability study medication . Expanded Access available protocol .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Key Have symptomatic AF 3 48 hour duration baseline . Be eligible cardioversion . Have adequate anticoagulation therapy cardioversion accordance standard practice recommend ACC/AHA/ESC guideline [ 1 ] . Be hemodynamically stable systolic blood pressure ( BP ) 100 mmHg less 160 mmHg diastolic BP le 95 mmHg screen baseline . Key Known suspect prolonged QT uncorrected QT interval &gt; 440 msec measure screen 12 lead ECG , familial long QT syndrome , previous torsades de pointes , ventricular fibrillation ; sustain ventricular tachycardia ( VT ) . Symptomatic bradycardia , sick sinus syndrome , ventricular rate le 50 beat per minute ( bpm ) document 12lead ECG screening . A QRS interval &gt; 140 msec . Atrial flutter . Significant valvular stenosis , hypertrophic obstructive cardiomyopathy , restrictive cardiomyopathy constrictive pericarditis . Documented previous episode second third degree atrioventricular ( AV ) block . Had myocardial infarction ( MI ) , acute coronary syndrome cardiac surgery within 30 day prior entry study . Uncorrected electrolyte imbalance serum potassium magnesium . Both K+ Mg2+ must correct prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>atrial fib</keyword>
	<keyword>AF</keyword>
</DOC>